

Jubilant gets USFDA nod

HT Correspondent

■ letters@hindustantimes.com

NEW DELHI: Pharmaceutical firm Jubilant Life Sciences on Tuesday said the company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Valsartan tablets. "We expect to launch this product immediately," the company said in a statement. The product is a generic version of Diovan tablets of Swiss drugmaker Novartis, used as an anti-hypertensive. "The current annualised US market size for Valsartan tablets USP, 40 mg, 80 mg, 160 mg, and 320 mg as per IMS is \$2 billion," it added.

Company